Study ID | Follow-up (week) | Randomized patients | Age (mean) | Male no. (%) | White no. (%) | ASCVD risk factor no. (%) | Baseline LDL-C (mean ± SD) (mg/dl) | Arms | LSM Difference (95% CI) percentage points | Total AEs, no (%) | |
---|---|---|---|---|---|---|---|---|---|---|---|
BA | Placebo | ||||||||||
Ray, K. K. 2019 [17] (NCT02666664) | 52 | 2230 (2:1) | 66 | 1628 (73.0) | 2139 (95.9) | 2176 (97.6) | 103.2 ± 29.4 | BA+statin vs. placebo +statin | −18.5 (− 20.7, −16.3) | 1167 (78.5) | 584 (78.7) |
Goldberg, A. C. 2019 [18] (NCT02991118) | 52 | 779 (2:1) | 64 | 496 (63.7) | 752 (96.5) | 736 (94.5) | 120.4 ± 37.9 | BA+statin vs. placebo +statin | −17.4 (−21, −13.9) | 366 (70.1) | 182 (70.8) |
Lalwani, N. D.2019 [19] (NCT02659397) | 4 | 68 (2:1) | 58 | 35 (51.5) | 49 (72.1) | NA | 76.4 ± 22.8 | BA+Ato vs. placebo +Ato | −22.2(− 36.4,-8.0) | 16 (35.6) | 5 (21.7) |
Ballantyne, C. M.2019 [20] (NCT03337308) | 12 | 301 (2:2:2:1) | 64.4 | 149 (49.5) | 243 (80.7) | 188 (62.5) | 149.7 ± 41 | BA+EZE vs. BA/EZE/placebo | −17.8(−25.1,-10.5)/−12.1(−19.1,-5.0)/− 33.7(− 43.9,-23.4) | 53 (62.4) | 58 (65.9)/47 (54.7)/18 (43.9) |
Laufs, U.2019 (NCT02988115) [21] | 24 | 345 (2:1) | 65.2 | 151 (43.8) | 307 (89.0) | NA | 157.6 ± 39.9 | BA vs. placebo | −18.9(−23.0,-14.9) | 150 (64.1) | 63 (56.8) |
Ballantyne, C. M.2018 [22] (NCT03001076) | 12 | 269 (2:1) | 64 | 104 (38.7) | 240 (89.2) | 269 (100) | 127.6 | BA+EZE vs. placebo + EZE | −36.5 (− 45.75, − 27.26) | 88 (48.6) | 39 (44.8) |
McGowan, Mary. 2017 [23] (NCT02659397) | 4 | 68 (2:1) | NA | NA | NA | NA | 86 | BA+statin vs. placebo +statin | −22 (−36.4, − 8) | NA | NA |
Thompson, P. D.2016 [24] (NCT01941836) | 12 | 349 | 60 | 244 (70.0) | 180 (51.6) | 131 (37.8) | 164.5 ± 25 | BA+EZE vs. placebo + EZE | −26.5 (−32.11, − 20.89) | 105 (52.8) | 31 (62) |
Ballantyne, C. M.2016 [25] (NCT02072161) | 12 | 133 (2:1) | 57 | 54 (40.6) | 111 (83.4) | NA | 135.4 ± 24 | BA+statin vs. placebo +statin | −16.7 (−26.7, − 6.7) | 43 (48.9) | 28 (62) |
Thompson, P. D.2015 [26] (NCT01751984) | 8 | 56 (2:1) | 62.6 | 28 (50) | 54 (96.4) | NA | 179 ± 35.7 | BA vs. placebo | −28.7(−35,4,−22.1) | 26 (70) | 17 (89) |
Newton, Roger S 2014 [27] | 8 | 58 | NA | NA | NA | NA | NA | BA+statin vs. placebo +statin | -22 (−32.4, −11.6) | NA | NA |
Gutierrez, M. J.2014 [28] (NCT01607294) | 4 | 60 (1:1) | 55.7 | 37 (61.7) | 57 (95) | NA | 126.8 ± 27.8 | BA vs. placebo | −39(−46.2,-31.7) | 14 (47) | 21 (70) |
Ballantyne, C. M.2013 [29] (NCT01262638) | 12 | 177 (1:1:1:1) | 57 | 98 (55.4) | 152 (85.9) | NA | 166.3 ± 24 | BA vs. placebo | −21.1(−26,-16.2) | 97 (92.9) | 33 (75) |